パイプライン

開発中の治療法

私たちの研究開発部門は、精神・神経疾患メカニズムの解明を目指しています。標準治療を見直し、精神・神経疾患領域で薬の開発が必要とする領域において、最もニーズが高い分野に対応する新たな治療法を患者さんに届けるという、ただ一つの目標に向かって歩んでいます

Hormonal / neuropeptide signaling
Project	Area
Eptinezumab (anti-CGRP mAb)¹ ¹⁰	Migraine prevention²	Filing
Mode of Action Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.
Lu AG09222 (anti-PACAP mAb)³	Migraine prevention²	2
Mode of Action Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology.
Lu AG13909 (anti-ACTH mAb)⁴	Neurohormonal dysfunctions	1

Circuitry / neuronal biology
Project	Area
Brexpiprazole⁵	PTSD⁶	Filing
Mode of Action Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation. *Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.
Lu AF28996 (D1-D2 agonist)⁷	Parkinson's disease	1
Mode of Action Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.
MAGLi program⁸	Neurology	1
Bexicaserin (5HT2C agonist)	Developmental and epileptic encephalopathies	3

Protein aggregation, folding and clearance
Project	Area	Phase 1	Phase 2	Phase 3
Amlenetug (anti α-synuclein mAb)	Synucleinopathies (MSA)				3

Neuroinflammation / Neuroimmunology
Project	Area	Phase 1	Phase 2	Phase 3
Lu AG22515 (CD40L blocker)⁹	Neurology				1

上記開発ステージは、ルンドベックグローバルの開発ステージとなります。

ルンドベックについてさらに知る

研究開発

私たちの中核は、新規でより良い治療法を研究開発することです

コミットメント

私たちは、脳の健康を推し進め、人生を変えることに注力しています

私たちのフォーカス

脳の健康がルンドベックにとって何を意味するのか